Communiqués Atea Pharmaceuticals, Inc.

Actions

AVIR

US04683R1068

Recherche biotechnologique et médicale

Marché Fermé - Nasdaq 22:00:00 30/09/2026			Varia. 5j.	Varia. 1 janv.
5,210 ^USD	+0,58%		-1,33%	+45,94%

15/09	Transcript : Atea Pharmaceuticals, Inc. Presents at Morgan Stanley 24th Annual Global Healthcare Conference, Sep-15-2026 12:20 PM
13/08	Atea Pharmaceuticals, Inc. : Morgan Stanley maintient son opinion neutre	ZM

Communiqués

08/09	Atea Pharmaceuticals to Present at the Morgan Stanley 24th Annual Global Healthcare Conference	AQ
12/08	Atea Pharmaceuticals Reports Second Quarter 2026 Financial Results and Provides Business Update	AQ
05/08	Atea Pharmaceuticals to Host Second Quarter 2026 Financial Results and Business Update Conference Call on August 12, 2026	AQ
28/07	Atea Pharmaceuticals Meets Both Its Primary and Secondary Endpoints in the Phase 3 C-BEYOND North America Trial Evaluating Bemnifosbuvir/Ruzasvir for Hepatitis C Virus	AQ
14/07	Atea Pharmaceuticals Initiates First-in-Human Phase 1 Clinical Trial of AT-587 for the Treatment of Hepatitis E Virus	AQ
25/06	Atea Pharmaceuticals Completes Patient Enrollment in Phase 3 C-FORWARD Trial Evaluating Bemnifosbuvir and Ruzasvir for Treatment of Hepatitis C Virus	AQ
27/05	Atea Pharmaceuticals Presents New Drug-Drug Interaction Results Supporting Potential Best-in-Class Profile of the Regimen of Bemnifosbuvir and Ruzasvir for the Treatment of Hepatitis C Virus at EASL Congress 2026	AQ
13/05	Atea Pharmaceuticals to Present Three Abstracts at EASL 2026 Congress Highlighting Progress Across Viral Hepatitis Pipeline	AQ
12/05	Atea Pharmaceuticals : Q1 26 IR Slide Deck 5 12 26 FINAL	PU
12/05	Atea Pharmaceuticals Reports First Quarter 2026 Financial Results and Provides Business Update	AQ
05/05	Atea Pharmaceuticals to Host First Quarter 2026 Financial Results and Business Update Conference Call on May 12, 2026	AQ
05/03	Atea Pharmaceuticals : Q4 FY25 IR Slide Deck 3 5 26 FINAL	PU
05/03	Atea Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update	AQ
26/02	Atea Pharmaceuticals to Host Fourth Quarter and Full Year 2025 Financial Results and Business Update Conference Call on March 5, 2026	AQ
24/02	Atea Pharmaceuticals Presents Preclinical Results Supporting First-in-Class Potential of AT-587 for Treatment of Hepatitis E Virus at CROI 2026	AQ
15/01	Atea Pharmaceuticals : 44th Annual J.P. Morgan Healthcare Conference Presentation (1eae58)	PU
08/01	Atea Pharmaceuticals to Highlight 2026 Strategic Priorities at the 44th Annual J.P. Morgan Healthcare Conference	AQ
06/01	Atea Pharmaceuticals to Present at the 44th Annual J.P. Morgan Healthcare Conference	AQ
22/12	Atea Pharmaceuticals Completes Patient Enrollment in North American Phase 3 Trial Evaluating Regimen of Bemnifosbuvir and Ruzasvir for Treatment of Hepatitis C Virus	AQ
19/11	Atea Pharmaceuticals to Present at the 8th Annual Evercore Healthcare Conference	AQ
12/11	Atea Pharmaceuticals : Q3 Slides November 12 2025 FINAL	PU
12/11	Atea Pharmaceuticals Reports Third Quarter 2025 Financial Results and Provides Business Update	AQ
07/11	Atea Pharmaceuticals Presents New Data Supporting the Fixed-Dose Combination of Bemnifosbuvir and Ruzasvir as a Potential Best-in-Class Regimen for Treatment of Hepatitis C Virus Infection at The Liver Meeting® 2025	AQ
05/11	Atea Pharmaceuticals to Host Third Quarter 2025 Financial Results and Business Update Conference Call on November 12, 2025	AQ
22/10/25	Atea Pharmaceuticals to Host Virtual HCV KOL Panel Event on November 13, 2025	AQ